Cargando…
Widefield fluorescence lifetime imaging of protoporphyrin IX for fluorescence‐guided neurosurgery: An ex vivo feasibility study
Achieving a maximal safe extent of resection during brain tumor surgery is the goal for improved patient prognosis. Fluorescence‐guided neurosurgery using 5‐aminolevulinic acid (5‐ALA) induced protoporphyrin IX has thereby become a valuable tool enabling a high frequency of complete resections and a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
WILEY‐VCH Verlag GmbH & Co. KGaA
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065606/ https://www.ncbi.nlm.nih.gov/pubmed/30636030 http://dx.doi.org/10.1002/jbio.201800378 |
_version_ | 1783505088635994112 |
---|---|
author | Erkkilä, Mikael T. Bauer, Bianca Hecker‐Denschlag, Nancy Madera Medina, Maria J. Leitgeb, Rainer A. Unterhuber, Angelika Gesperger, Johanna Roetzer, Thomas Hauger, Christoph Drexler, Wolfgang Widhalm, Georg Andreana, Marco |
author_facet | Erkkilä, Mikael T. Bauer, Bianca Hecker‐Denschlag, Nancy Madera Medina, Maria J. Leitgeb, Rainer A. Unterhuber, Angelika Gesperger, Johanna Roetzer, Thomas Hauger, Christoph Drexler, Wolfgang Widhalm, Georg Andreana, Marco |
author_sort | Erkkilä, Mikael T. |
collection | PubMed |
description | Achieving a maximal safe extent of resection during brain tumor surgery is the goal for improved patient prognosis. Fluorescence‐guided neurosurgery using 5‐aminolevulinic acid (5‐ALA) induced protoporphyrin IX has thereby become a valuable tool enabling a high frequency of complete resections and a prolonged progression‐free survival in glioblastoma patients. We present a widefield fluorescence lifetime imaging device with 250 mm working distance, working under similar conditions such as surgical microscopes based on a time‐of‐flight dual tap CMOS camera. In contrast to intensity‐based fluorescence imaging, our method is invariant to light scattering and absorption while being sensitive to the molecular composition of the tissue. We evaluate the feasibility of lifetime imaging of protoporphyrin IX using our system to analyze brain tumor phantoms and fresh 5‐ALA‐labeled human tissue samples. The results demonstrate the potential of our lifetime sensing device to go beyond the limitation of current intensity‐based fluorescence‐guided neurosurgery. [Image: see text] |
format | Online Article Text |
id | pubmed-7065606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | WILEY‐VCH Verlag GmbH & Co. KGaA |
record_format | MEDLINE/PubMed |
spelling | pubmed-70656062020-03-16 Widefield fluorescence lifetime imaging of protoporphyrin IX for fluorescence‐guided neurosurgery: An ex vivo feasibility study Erkkilä, Mikael T. Bauer, Bianca Hecker‐Denschlag, Nancy Madera Medina, Maria J. Leitgeb, Rainer A. Unterhuber, Angelika Gesperger, Johanna Roetzer, Thomas Hauger, Christoph Drexler, Wolfgang Widhalm, Georg Andreana, Marco J Biophotonics Full Articles Achieving a maximal safe extent of resection during brain tumor surgery is the goal for improved patient prognosis. Fluorescence‐guided neurosurgery using 5‐aminolevulinic acid (5‐ALA) induced protoporphyrin IX has thereby become a valuable tool enabling a high frequency of complete resections and a prolonged progression‐free survival in glioblastoma patients. We present a widefield fluorescence lifetime imaging device with 250 mm working distance, working under similar conditions such as surgical microscopes based on a time‐of‐flight dual tap CMOS camera. In contrast to intensity‐based fluorescence imaging, our method is invariant to light scattering and absorption while being sensitive to the molecular composition of the tissue. We evaluate the feasibility of lifetime imaging of protoporphyrin IX using our system to analyze brain tumor phantoms and fresh 5‐ALA‐labeled human tissue samples. The results demonstrate the potential of our lifetime sensing device to go beyond the limitation of current intensity‐based fluorescence‐guided neurosurgery. [Image: see text] WILEY‐VCH Verlag GmbH & Co. KGaA 2019-02-20 2019-06 /pmc/articles/PMC7065606/ /pubmed/30636030 http://dx.doi.org/10.1002/jbio.201800378 Text en © 2019 The Authors. Journal of Biophotonics published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Full Articles Erkkilä, Mikael T. Bauer, Bianca Hecker‐Denschlag, Nancy Madera Medina, Maria J. Leitgeb, Rainer A. Unterhuber, Angelika Gesperger, Johanna Roetzer, Thomas Hauger, Christoph Drexler, Wolfgang Widhalm, Georg Andreana, Marco Widefield fluorescence lifetime imaging of protoporphyrin IX for fluorescence‐guided neurosurgery: An ex vivo feasibility study |
title | Widefield fluorescence lifetime imaging of protoporphyrin IX for fluorescence‐guided neurosurgery: An ex vivo feasibility study |
title_full | Widefield fluorescence lifetime imaging of protoporphyrin IX for fluorescence‐guided neurosurgery: An ex vivo feasibility study |
title_fullStr | Widefield fluorescence lifetime imaging of protoporphyrin IX for fluorescence‐guided neurosurgery: An ex vivo feasibility study |
title_full_unstemmed | Widefield fluorescence lifetime imaging of protoporphyrin IX for fluorescence‐guided neurosurgery: An ex vivo feasibility study |
title_short | Widefield fluorescence lifetime imaging of protoporphyrin IX for fluorescence‐guided neurosurgery: An ex vivo feasibility study |
title_sort | widefield fluorescence lifetime imaging of protoporphyrin ix for fluorescence‐guided neurosurgery: an ex vivo feasibility study |
topic | Full Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065606/ https://www.ncbi.nlm.nih.gov/pubmed/30636030 http://dx.doi.org/10.1002/jbio.201800378 |
work_keys_str_mv | AT erkkilamikaelt widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy AT bauerbianca widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy AT heckerdenschlagnancy widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy AT maderamedinamariaj widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy AT leitgebrainera widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy AT unterhuberangelika widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy AT gespergerjohanna widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy AT roetzerthomas widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy AT haugerchristoph widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy AT drexlerwolfgang widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy AT widhalmgeorg widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy AT andreanamarco widefieldfluorescencelifetimeimagingofprotoporphyrinixforfluorescenceguidedneurosurgeryanexvivofeasibilitystudy |